Gorga v. Uniroyal Chemical Corp.

697 A.2d 731, 45 Conn. Super. Ct. 24, 45 Conn. Supp. 24, 1996 Conn. Super. LEXIS 3520
CourtConnecticut Superior Court
DecidedDecember 12, 1996
DocketFile CV960132014
StatusPublished
Cited by3 cases

This text of 697 A.2d 731 (Gorga v. Uniroyal Chemical Corp.) is published on Counsel Stack Legal Research, covering Connecticut Superior Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Gorga v. Uniroyal Chemical Corp., 697 A.2d 731, 45 Conn. Super. Ct. 24, 45 Conn. Supp. 24, 1996 Conn. Super. LEXIS 3520 (Colo. Ct. App. 1996).

Opinion

FINEBERG, J.

On March 28, 1996, the plaintiff, Joseph Gorga, a resident of New Jersey, filed a class action complaint in three counts against the defendants. The plaintiff seeks to bring this action on behalf of “all persons, other than defendants, their agents, affiliates and auditors, who purchased Uniroyal Chemical common stock on the public offering of such securities on or about March 16,1995, and in the aftermarket through *25 and including September 20, 1995” (class period). The complaint asserts federal securities law claims against the defendants for alleged violations of §§ 11, 12 (2) and 15 of the federal Securities Act of 1933 (1933 act), 15 U.S.C. §§ 77k (a), 771 (2) and 77o, 1 and also asserts a claim under the Connecticut Uniform Securities Act (CUSA). In his complaint, the plaintiff alleges the following facts upon which these claims are based.

The named defendant, the Uniroyal Chemical Corporation (Uniroyal Chemical), is a publicly traded Delaware corporation, with its principal place of business located in Middlebury, Connecticut. The defendant Morgan Stanley and Company, Inc. (Morgan Stanley) is an investment banking firm located in New York City. The complaint also names as individual defendants Uniroyal Chemical’s “controlling persons”: Robert J. Mazaika, its chairman of the board, chief executive officer and president; John T. Stofko, its former vice president and chief financial officer; Charles E. Williams, its controller; and, Thomas M. Begel, Beri Bernhard, Harry Corless and Paul Kolton, each directors of Uniroyal Chemical.

In March, 1995, Uniroyal Chemical undertook a public offering of 13,350,000 shares of its common stock, priced at $12 per share. Morgan Stanley served as the co-lead underwriter for Uniroyal Chemical’s initial public offering. In connection with this initial public offering, Uniroyal Chemical filed with the federal Securities and Exchange Commission (SEC) and disseminated to the public a registration statement and prospectus, effective March 16, 1995. Since the March 16, 1995 initial public offering, Uniroyal Chemical’s common stock has been listed and traded on the National Association of Securities Dealers Automatic Quotation System (NASDAQ).

*26 The complaint alleges three causes of action against all the defendants. In count one, the plaintiff alleges that the aforementioned registration statement and prospectus “contained untrue statements of material facts and omitted to state material facts required to be stated therein which were necessary to make the statements therein not misleading,” in violation of § 11 of the 1933 act. Specifically, the plaintiff alleges thirteen distinct misrepresentations and omissions by the defendants regarding the prospectus. According to the plaintiff, these misrepresentations and omissions directly and proximately resulted in the price for Uniroyal Chemical’s shares being “artificially inflated in the [initial public offering] and in the aftermarket during the Class Period,” resulting in the plaintiff and members of the class sustaining “substantial damages.” Count two of the complaint incorporates count one in its entirety, and further alleges that the defendants violated § 12 (2) of the 1933 act, 15 U.S.C. § 771 (2). In count three, the plaintiff incorporates count two in its entirety, further alleging that the defendants’ conduct violated CUSA, General Statutes § 36b-2 et seq.

On June 21, 1996, Uniroyal Chemical and the individual defendants filed a motion to dismiss and a motion to strike the plaintiffs complaint, accompanied by a single memorandum of law in support of both motions. On June 24, 1996, Morgan Stanley filed a motion to dismiss and/or strike along with its own supporting memorandum of law. In its memorandum, Morgan Stanley incorporates the legal arguments and factual analysis contained in Uniroyal Chemical’s memorandum, while also setting forth additional arguments in particular to Morgan Stanley. Thereafter, on September 4,1996, the plaintiff filed a memorandum in opposition to the defendants’ motions. On October 7, 1996, both Morgan Stanley and Uniroyal Chemical, with the individual defendants, filed reply memoranda. On October 15, *27 1996, the plaintiff filed a reply memorandum of law in further opposition to the defendants’ motions.

On October 15, 1996, this court heard arguments on all pending motions. Based on the plaintiffs indicated ability to plead proper standing to sue, the defendants agreed to withdraw their respective motions to dismiss, and the court dismissed the same. Additionally, the court denied Uniroyal Chemical’s motion to strike as its motion required the court to refer to documentation outside the complaint. See Liljedahl Bros., Inc. v. Grigsby, 215 Conn. 345, 348, 576 A.2d 149 (1990). As Morgan Stanley’s motion to strike incorporated the arguments and factual analysis of Uniroyal Chemical, the court also, for the same reason, denied its motion to strike as to count one. 2 The only items remaining for the court to rule upon, therefore, are the additional arguments raised by Morgan Stanley regarding counts two and three of the plaintiffs complaint, as those counts relate to Morgan Stanley. 3

“The function of a motion to strike is to test the legal sufficiency of a pleading .... See Practice Book § 152.” Napoletano v. CIGNA Healthcare of Connecticut, Inc., 238 Conn. 216, 232, 680 A.2d 127 (1996). A motion to strike contests “the legal sufficiency of the allegations of any complaint ... to state a claim upon which relief can be granted.” (Internal quotation marks omitted.) Novametrix Medical Systems, Inc. v. BOC Group, Inc., 224 Conn. 210, 214-15, 618 A.2d 25 (1992). “In ruling on a motion to strike, the court is limited to the facts alleged in the complaint. The court must *28 construe the facts in the complaint most favorably to the plaintiff.” (Internal quotation marks omitted.) Id., 215. “If facts provable in the complaint would support a cause of action, the motion to strike must be denied.” Waters v. Autuori, 236 Conn. 820, 826, 676 A.2d 357 (1996).

Morgan Stanley moves to strike count two of the plaintiffs complaint on the ground that the count fails to allege sufficient facts to impose liability on Morgan Stanley under § 12 (2) of the 1933 act. Specifically, Morgan Stanley claims that the plaintiff fails adequately to allege that he purchased his Uniroyal Chemical stock from or was solicited by Morgan Stanley.

Section 12 (2) of the 1933 act provides in pertinent part that any person who “sells a security ...

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Winford v. Advest, Inc., No. Cv 00-0598424-S (Dec. 19, 2000)
2000 Conn. Super. Ct. 15763 (Connecticut Superior Court, 2000)
Rocque v. Sound Manufacturing, Inc., No. Cv 99 0588424s (Dec. 7, 1999)
1999 Conn. Super. Ct. 15777 (Connecticut Superior Court, 1999)

Cite This Page — Counsel Stack

Bluebook (online)
697 A.2d 731, 45 Conn. Super. Ct. 24, 45 Conn. Supp. 24, 1996 Conn. Super. LEXIS 3520, Counsel Stack Legal Research, https://law.counselstack.com/opinion/gorga-v-uniroyal-chemical-corp-connsuperct-1996.